Causes and outcomes of markedly elevated C-reactive protein levels

Canadian Family Physician

Volumn 63, Issue 6, 2017, Pages e316-e323

  Landry, Alexander ^a   Docherty, Peter ^b   Ouellette, Sylvie ^b   Cartier, Louis Jacques ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MONCTON HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; IMMUNOSUPPRESSIVE AGENT; RITUXIMAB; STEROID; TUMOR NECROSIS FACTOR INHIBITOR; BIOLOGICAL MARKER;

ABNORMAL VALUE; ABSCESS; ADULT; ADVERSE DRUG REACTION; AGE; AGED; ANCA ASSOCIATED VASCULITIS; ARTHRITIS; ARTICLE; BACTERIAL ARTHRITIS; BLOOD VESSEL GRAFT; BLOODSTREAM INFECTION; C REACTIVE PROTEIN TEST KIT; CAUSAL ATTRIBUTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLON CANCER; COMORBIDITY; CRYSTAL INDUCED ARTHRITIS; DISEASE MODEL; ENDOCARDITIS; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL INFECTION; GIANT CELL ARTERITIS; GRAFT INFECTION; HEMATOLOGIC MALIGNANCY; HEMATOMA; HOSPITAL PATIENT; HUMAN; IMMUNOASSAY ANALYZER; INFECTIOUS ARTHRITIS; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INTESTINE ISCHEMIA; INTESTINE OBSTRUCTION; LEUKOCYTE COUNT; LEUKOCYTOSIS; LEUKOPENIA; LIMB ISCHEMIA; LUNG CANCER; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MEDICAL RECORD REVIEW; MORTALITY RATE; OSTEOMYELITIS; OUTPATIENT; PATIENT-REPORTED OUTCOME; PERICARDITIS; PHARYNGITIS; PREVALENCE; PRIMARY INFECTION; RHABDOMYOLYSIS; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; SEX; SKIN INFECTION; SOFT TISSUE INFECTION; SOLID MALIGNANT NEOPLASM; SYSTEMIC LUPUS ERYTHEMATOSUS; URINARY TRACT INFECTION; VEIN THROMBOSIS; VIRUS INFECTION; ADOLESCENT; CLASSIFICATION; INFECTION; MIDDLE AGED; NONPARAMETRIC TEST; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; C-REACTIVE PROTEIN; FEMALE; HUMANS; INFECTION; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 85020811665     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340(6):448-54.
2. Erratum in: N Engl J Med 1999;340(17):1376.
3. Koenig W, Löwel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 2004;109(11):1349-53. Epub 2004 Mar. 15.
4. Chaturvedi AK, Caporaso NE, Katki HA, Wong HL, Chatterjee N, Pine SR, et al. C-reactive protein and risk of lung cancer. J Clin Oncol 2010;28(16):2719-26. Epub 2010 Apr. 26.
5. Morley JJ, Kushner I. Serum C-reactive protein levels in disease. Ann N Y Acad Sci 1982;389:406-18.
6. Gaitonde S, Samols D, Kushner I. C-reactive protein and systemic lupus erythematosus. Arthritis Rheum 2008;59(12):1814-20.
7. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003;111(12):1805-12.
8. Erratum in: J Clin Invest 2003;112(2):299.
9. Vanderschueren S, Deeren D, Knockaert DC, Bobbaers H, Bossuyt X, Peetermans W. Extremely elevated C-reactive protein. Eur J Intern Med 2006;17(6):430-3.
10. BC Biomedical Laboratories. New MSP laboratory medicine funding agreement. Physicians' Newsletter 2010; XII (3):1-3.